Molecular Imaging of the Lung- Phase 1 (R01)

Post Date

October 24th 2011

Application Due Date

February 1st 2012

Funding Opportunity Number

RFA-HL-12-036

CFDA Number(s)

93.838

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Funding

• Estimated Total Funding:

  $2800000

• Award Range:

  $None - $250000

Grant Description

This FOA, issued by the National Heart, Lung and Blood Institute (NHLBI), National Institute of Health, invites Research Project Grant (R01) applications to develop novel in vivo imaging reagents and technologies such as molecular probes that target pathways or cells involved in development and pathobiology of pulmonary diseases. In Phase I investigators will identify appropriate molecular targets with relevance to lung health and diseases, develop the appropriate molecular probes, in combination with innovative imaging approaches, and validate the developed probes in cells and in vivo animal models. NHLBI anticipates announcing a companion FOA for a Phase II that will be released at a later date, to support studies to extend molecular imaging methods to human studies for clinical applications in lung disease. Both phases will be open competitions. The long-term goal is to use molecular imaging to facilitate early detection and diagnosis of lung disease, enable noninvasive monitoring of lung disease progression and prognosis, and accelerate progress in cell-specific drug delivery and therapies.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-12-036.html